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Doses of endothelin have natriuretic effects in conscious rats with
cirrhosis and ascites. MAP, RPF, GFR, V and UNaV were measured in
nine conscious control and in 11 conscious cirrhotic rats with ascites
before and following two bolus injections (100 and 600 pmollkg body wt)
of endothelin (ET). PRA and plasma concentration of aldosterone and
ANP were measured in basal conditions and following the high dose
ET. ET induced similar increase in MAP and decrease in RPF and GFR
in control and cirrhotic rats. High-dose ET produced a significant
reduction in UNaV in control rats (from 2.22 0.46 to 1.14 0.28
Eq/min, P < 0.01). By contrast, it induced marked natriuresis in
cirrhotic rats (from 0.76 0.18 to 2.31 0.70 sEq/min, P <0.05). ET
significantly increased aldosterone (control rats: 59.3 2.2 vs. 85.4
7.4 ng/dl, P < 0.025; cirrhotic rats: 115.0 15.8 vs. 163.9 30.8, ng/dl,
P < 0.05) and ANP (control rats: 20.1 3.4 vs. 42.7 7.7, fmol/ml, P
< 0.025; cirrhotic rats: 107.5 17.3 vs. 214.2 41.1, fmol/ml, P <
0.025) and significantly suppressed PRA (control rats: 2.5 0.5 vs. 0.2
0.04, ng/ml hr, P < 0.025; cirrhotic rats: 16.6 2.9 vs. 5.0 1.1,
ng/ml hr, P < 0.01) in both groups of animals, These results indicate
that ET has marked natriuretic properties in cirrhosis with ascites due
to inhibition of tubular sodium reabsorption.
Endothelin (ET) is a 21 amino acid, endothelium-derived
peptide with powerful biological effects [1]. The administration
of pharmacological doses of this peptide to experimental ani-
mals elicits a marked and sustained increase in arterial pressure
and systemic vascular resistance, a decrease in cardiac output,
a profound reduction in renal plasma flow (RPF) and glomerular
filtration rate (GFR) and a fall in sodium excretion [2—7]. In
addition, in vivo and in vitro studies show that ET also
modulates the synthesis and release of several endogenous
vasoactive substances such as renin [2, 5, 8—12], aldosterone [2,
5, 13, 14], vasopressin (AVP) (2, 5, 15), atrial natriuretic peptide
(ANP) [2, 5, 16—20] and norepinephrine (NE) [5, 21]. Once
secreted by the endothelial cells, ET is rapidly metabolized.
Consequently, ET is thought to act nearby its site of synthesis
to regulate microcirculatory hemodynamics and the release of
vasoactive hormones.
In the current study, pharmacological doses of ET were given
to conscious control rats and cirrhotic rats with ascites. The aim
of the study was to assess the effect of ET on systemic and renal
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hemodynamics, sodium excretion, plasma renin activity (PRA)
and plasma levels of aldosterone and ANP in cirrhosis with
ascites.
Methods
The study was performed in 11 conscious, adult male Wistar
rats with cirrhosis and ascites and nine control rats. Both
groups were fed ad libitum with standard chow and distilled
water containing phenobarbital (0.3 g/liter) as drinking fluid.
Cirrhosis was induced by Cd4, which was administered by
inhalation twice weekly (Monday and Friday) following a
method described elsewhere [22, 231. Cirrhotic rats were stud-
ied after having developed ascites. Since previous studies from
our laboratory have shown that rats treated with CCI4 and
phenobarbital develop ascites 9 to 12 weeks after starting the
cirrhosis induction program [24], control rats were studied on
week 9 to 12 after the initiation of the study.
Cirrhotic and control rats were anesthetized with ketamine
(50 mg/kg body wt) and prepared with P-SO catheters in the right
carotid artery, jugular vein and bladder. Catheters were tun-
neled subcutaneously, exteriorized at the nape of the neck, run
through a flexible stainless sheath and connected to a swivel
(Harvard, South Patrick, Massachusetts, USA). The sheath
was attached to a harness made of polystyrene which the animal
wore. The arterial catheter was connected to a highly sensitive
transducer and a multichannel recorder (MX4P and MT4,
Lectromed Ltd, Jersey, Chanel Islands, UK) and continuously
perfused with Ringer solution (1 mI/hr) using a continuous flow
system (Critiflo, Gould mc, Oxnard, California, USA) to main-
tain patency. Pulsatile and mean arterial pressure (MAP) and
pulse period were recorded. Heart rate (HR) was calculated
from the pulse period.
Animals were placed in rectangular cages with no restriction
of movement and allowed to recover from surgery for about 24
hours. MAP and HR were then monitored until stable for at
least 30 minutes. Thereafter a 3 ml blood sample was taken to
measure PRA and plasma concentration of aldosterone and
ANP. Blood was immediately centrifuged at 4°C and the plasma
frozen at —20°C until further analysis. Packed cells were
reconstituted to an equal volume with Ringer solution and
reinfused over a period of three minutes. A priming dose of
'251-Iothalamate (0.37 MCi) and PAH (1.8 mg) was given
through the jugular vein, followed by a constant infusion (2
ml/hr) of a Ringer solution containing '251-Iothalamate (0.375
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CiIml) and PAH (1.8 mg/mI). After allowing one hour for
equilibration, two baseline 20-minute urine collections were
completed for sodium, '251-Iothalamate and PAH measure-
ments. In the middle of each period, a blood sample (0.5ml)
was obtained through the arterial catheter to determine hema-
tocrit, sodium, potassium, osmolality and plasma levels of
'251-Iothalamate and PAH. Packed cells were reinfused as
above described. Thereafter, animals received an intravenous
bolus (administered over I mm) of 100 pmol/kg body wt of
synthetic porcine ET (Peptide Institute Inc., Osaka, Japan)
dissolved in distilled water (100 pmol/ml) containing 0.01%
BSA. Five minutes later, a 30-minute urine collection was
performed. A second bolus of ET (600 pmol/kg body wt)
dissolved in 0.01% BSA in water (600 pmol/ml) was then
administered, and after five minutes a 30-minute urine collec-
tion was obtained. At the end of this period a blood sample (3
ml) was again obtained to measure PRA and plasma concentra-
tion of aldosterone and ANP. Since rats were not allowed to
recover after the first dose, results obtained following the
second bolus represent the response to a cumulative dose.
A liver specimen was obtained from the middle lobe of each
animal. Liver specimens were fixed in 10% buffered formalin
and stained with hematoxylin-eosin, reticulin and Masson'
trichome for histologic examination.
The protocols were performed according to the Hospital
Clinic i Provincial Committee's criteria for the care and use of
laboratory animals.
Measurements and statistical analysis
Plasma osmolality was measured from osmometric depres-
sion of the freezing point (Advanced Instruments Osmometer
3M0, Needham, HTs, Massachusetts, USA) and sodium and
potassium concentration by flame photometry (IL 943, Instru-
mentation Laboratory, Lexington, Massachusetts, USA). PRA
was estimated by radioimmunoassay measurement (Clinical
Assay, Baxter, Cambridge, Massachusetts, USA) of the gener-
ated angiotensin I in conditions described elsewhere [25].
Plasma aldosterone was measured by using a commercial kit
(Coat-A-Count Aldosterone, Diagnostic and Products Corpora-
tion, Los Angeles, California). ANP was measured as previ-
ously described [26]. Statistical analysis of results was per-
formed by using the one way analysis of variance, the paired
and unpaired Student's t-tests, and the two variable regression
analysis. Results are given as mean SEM and are considered
significant at a P level of 0.05 or less. Maximal changes in MAP
and HR were used for statistical analysis.
Results
The liver histology of all animals treated with CCI4 showed
cirrhosis. All these animals also had ascites at the time of the
study, the ascites volume ranging from 2 to 30 ml. Control rats
had no appreciable alteration in liver histology.
Table 1 shows baseline MAP, HR, serum electrolytes, serum
osmolality, renal hemodynamics, urine volume (V), sodium
excretion (UNaV), PRA, plasma concentration of aldosterone
and ANP in cirrhotic and control rats. As compared to control
animals, cirrhotic rats showed a significantly reduced MAP,
serum sodium concentration, serum osmolality, V and UNaV
and a significantly increased PRA and plasma concentration of
aldosterone and ANP. No differences existed between control
P
Cirrhotic Control values
MAP mm Hg 107 2 120 3 <0.01
HR beats/mm 384 10 399 10 NS
Serum sodium mEq/liter 133 I 138 1 <0.05
Serum potassium 3.9 0.2 4.1 0.1 NS
mEqlliter
Serum osmolality 290 2 299 1 <0,01
mOsni/kg
RPF mI/mm 12.1 2.2 12.4 1.5 NS
GFR mI/mm 3.61 0.49 4.21 0.41 NS
V d/min 15.2 3.5 37.0 5.5 <0.005
UNaV Eq/mmn 0.76 0.18 2.22 0.46 <0.025
PRA ng/ml. hr 16.6 2.9 2.5 0.5 <0.01
Plasma aldosterone ng/dI 115.0 15.8 59.3 2.2 <0.025
ANPfmol/ml 107.5 17.3 20.1 3.4 <0.001
and cirrhotic animals with respect to HR, serum potassium
concentration, GFR and RPF.
Figure 1 shows a representative chart record of blood pres-
sure changes after the administration of low and high-dose of
ET in cirrhotic and control rats. Bolus ET administration was
associated with a very brief initial depressor response which
occurred within the first minute. The hypotensive effect was
observed with both doses, being more marked with the high
dose (cirrhotic: 73 2 mm Hg, P < 0.001 with respect to
baseline values; control: 86 3 mm Hg, P < 0.001) than with
the low one (cirrhotic: 87 3 mm Hg, P < 0.001; control: 101
4, P < 0.001). Following this transient hypotensive effect,
low-dose ET induced a significant increase in MAP (cirrhotic:
112 2 mm Hg, P < 0.05 with respect to baseline values;
Table 1. Baseline values for cirrhotic and control rats
ET (100 pmollkg( El (600 pmollkg)
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Data are from Student's 1-test for unpaired data. Abbreviations are:
Mean arterial pressure (MAP), heart rate (HR), renal plasma flow
(RPF), glomerular filtration rate (GFR), urine volume (V), sodium
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Fig. 1. Representative chart record of blood pressure changes in
control (A) and cirrhotic rats (B) following bolus endothelin adminis-
tration.
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Fig. 2. Absolute increase in mean arterial pressure after giving low-
dose (100 pmol/kg body wt) and high-dose (600 pmol/kg body wt)
endothelin to control (empty bars) and cirrhotic (shadowed bars) rats.
P < 0.001 vs. low-dose (Student's 1-test for paired data).
Table 2. Effects of bolus endothelin administration on renal
hemodynamics in cirrhotic and control rats
Basal
Endothelin
100 pmolikg 600 pmolikg
Renal plasma flow
mi/mm
Cirrhotic 12.1 2.2 6.3 l.5C 3.5 0.7
Control 12.4 1.5 6.9 1.28 44
Glomerular filtration rate
mi/mm
Cirrhotic 3.61 0.49 2.50 0.60 1.77 0.37e
Control 4.21 0.41 3.28 0.38 1.89 0.46"
Filtration fraction
Cirrhotic 0.36 0.07 0.42 0.08 0.50 0.07




Cirrhotic 7.39 1.22 18.23 4.268 32.99 7.81C
Control 6.20 0.72 14.00 2.24C 23.63 2.68e
a p <0.05, b P <0.025, C P <0.01, d P <0.005, e P <0.001. versus
baseline values (Student's 1-test for paired data).
control: 128 3 mm Hg, P <0.001). This hypertensive effect
was more pronounced with high-dose ET (cirrhotic: 129 3
mm Hg, P < 0.001; control: 143 3mm Hg, P < 0.001) and was
associated with bradycardia (cirrhotic: 320 8 beats/mm, P <
0.001; control: 349 20 beats/mm, P < 0.005). Since cirrhotic
rats had arterial hypotension in baseline conditions, MAP
following the administration of ET was always lower in cir-
rhotic than in control rats. However the absolute increase in
arterial pressure induced by the administration of the peptide
was similar in both groups of animals (Fig. 2).
The effect of ET on renal hemodynamics in cirrhotic and
control rats is shown in Table 2. The administration of ET was
associated with a similar dose-dependent decrease in RPF in the
two groups of animals. Low- and high-dose ET decreased RPF
by 47% and 71%, respectively, in cirrhotic rats and by 45% and
66% in control animals. Low-dose ET did not significantly
affect GFR in the two groups of animals. However, high-dose
ET decreased GFR by 45% in cirrhotic and by 55% in control
Table 3. Effects of bolus endothelin administration on renal sodium
handling in cirrhotic and control rats
Basal
Endothelin
100 pmolIkg 600 pmol/kg
Urine volume ,.d/min
Cirrhotic 15.2 3.5" 23.3 8.6 22.5 6.1
Control 37.0 5.5 21.4 2.5" 18.4 5•5a
Urinary sodium excretion
p.Eqimin
Cirrhotic 0.76 0.18 1.73 0.61 2.31 0.70a
Control 2.22 0.46 1.52 0.41 1.14 0.28'
Filtered sodium load
i.sEqlmin
Cirrhotic 485 69 341 83 244 52
Control 587 62 461 57 263
Fractional sodium
excretion %
Cirrhotic 0.13 0.03 0.55 Ol5' 0.88 0.23"
Control 0.38 0.08 0.32 0.07 0.54 0.15
8 P<0.05," P <0.025, C P <0.01, ' P<0.005, e P <0.001. versus
baseline values (Student's t-test for paired data); and P < o.oos, P <
0.025 versus control rats (Student's 1-test for unpaired data).
animals. Since the percent decrease of GFR following ET
administration was always lower than that of RPF, there was a
tendency of filtration fraction to increase. The calculated renal
vascular resistance markedly increased following low- and
high-dose ET in both groups of animals.
Table 3 shows the effect of ET on V and renal sodium
metabolism in control and cirrhotic rats. In control rats, high-
dose ET induced a significant reduction in both filtered sodium
load and UN8)V. These two parameters also decreased following
low-dose ET, but differences were not statistically significant.
The effect of ET on renal sodium metabolism in cirrhotic rats
was opposite to that observed in control animals. Both low- and
high-dose ET increased sodium excretion in conscious rats with
cirrhosis and ascites. The natriuretic effect of ET in cirrhotic
rats was particularly striking following the administration of
high-dose ET, which increased UNaV to values observed in
control rats in baseline conditions. This natriuretic effect oc-
curred despite a significant fall in filtered sodium load, indicat-
ing a marked increase in fractional sodium excretion due to
inhibition of tubular sodium reabsorption. The natriuretic effect
of ET in cirrhotic rats correlated inversely with the percent
decrease in GFR induced by the peptide (r —0.605, P <
0.005), animals with lower sodium excretion after ET adminis-
tration being those with a greater decrease in GFR. Low- and
high-dose ET significantly reduced urine volume in control but
not in cirrhotic rats.
The effect of ET on PRA and plasma concentration of
aldosterone and ANP is depicted in Figure 3. ET administration
significantly suppressed PRA and significantly increased plasma
concentration of aldosterone and ANP in both, control and
cirrhotic rats.
Discussion
During the last few years a considerable amount of data has
been obtained indicating that vascular endothelium, by secret-
ing vasoconstrictor and vasodilator substances, could play an
important role in the regulation of arterial pressure and volume
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initial, short-lived, systemic hypotensive response followed by
a sustained systemic hypertensive effect which was associated,
at the high-dose, with bradycardia. Both, the hypotensive and
hypertensive effects of ET were dose-dependent. This systemic
hemodynamic response to bolus ET administration has previ-
ously been described in conscious and anesthetized rats [1, 3,4,
6, 7]. The reason for the initial hypotensive effect is not known.
It has been proposed that bolus ET could induce the release of
endothelial vasodilators, such as prostaglandins and/or endo-
thelium-derived relaxing factor, that may produce the initial
short-lived hypotension [31]. Cardiodynamic studies have pre-
viously demonstrated that the increase in arterial pressure that
follows the hypotensive phase occurs in the setting of a de-
crease or without changes in cardiac output, indicating that the
hypertensive effect of ET is due to an increase in peripheral
vascular resistance [2, 4]. The systemic hemodynamic effects
induced by bolus ET administration to rats with cirrhosis and
ascites were qualitatively similar to that observed in control
animals, the magnitude of the response also being the same.
This finding contrasts sharply with the results of previous
studies in cirrhotic patients and in several models of experimen-
tal cirrhosis which show an impaired response to the effect of
other endogenous vasoconstrictor substances, such as norepi-
nephrine [32, 331, angiotensin II [34, 35] and vasopressin [361. It
has been hypothesized that a non-specific decreased ability of
vascular smooth muscle to contract to pressor stimuli could be
responsible for the decreased pressor response to these vaso-
constrictors in cirrhosis. However, there is no general agree-
ment on this point since other authors [34, 371 found a normal
response to norepinephrine in rats with experimental cirrhosis.
The results of the current investigation also argued against a
generalized impaired vasoconstrictor response in cirrhosis,
since such a defect should also blunt the response to ET.
Administration of ET to control and cirrhotic rats with ascites
resulted in a pronounced dose-dependent increase in renal
vascular resistance which led to a reduction in RPF and, to a
lesser extent, in GFR. This greater reduction in RPF suggests a
predominant effect of ET on efferent arterioles. These findings
indicate that the renal vascular reactivity to the pressor effect of
ET is also maintained in rats with cirrhosis and ascites, and
confirm previous investigations indicating that the renal vascu-
lar bed is very sensitive to the vasoconstrictor effect of this
peptide [38, 39].
In spite that ET-induced changes in arterial pressure and
renal hemodynamics were similar in cirrhotic and control rats,
opposite effects on sodium excretion were observed in the two
groups of animals. As shown by previous studies [2, 3, 5, 7],
high dose ET was associated with a reduction in sodium
excretion in control rats. This antinatriuretic effect of ET
occurred in the setting of a marked decrease in filtered sodium
load and without significant changes in fractional sodium excre-
tion, indicating that the sodium retaining effect caused by the
systemic administration of ET is mainly due to the impairment
in GFR. By contrast, high dose ET had natriuretic activity in
conscious cirrhotic rats with ascites, which was so remarkable
that it normalized sodium excretion in these animals. This
phenomenon occurred despite a profound reduction in filtered
sodium load, and was secondary to a marked inhibition of
tubular sodium reabsorption, as indicated by the increase in























Fig. 3. Plasma renin activity (PRA), and plasma concentration of
aldosterone and atrial natriuretic peptide (ANP) in control and cir-
rhotic rats, in baseline conditions (empty bars) and following endothe-
un administration (shadowed bars). ap <o•o5, bp<0.025 and C <0.01
vs. baseline values (Student's t-test for paired data); * < 0.01 and **
< 0.005 vs. control rats (Student's t test for unpaired data).
the 21-amino acid peptides termed endothelins are the only ones
fully characterized so far [1]. In humans and other mammals,
three structurally and pharmacology separate ET isopeptides
have been described: human or porcine ET (also named Endo-
thelin-l), Endothelin-2, and rat ET (also named Endothelin-3)
[29]. Human or porcine ET is known to be synthesized by the
endothelial cells. The origin of Endothelin-2 and rat ET is not
fully established [30]. Human ET derives from a large pre-
propeptide of 203 amino acids which is processed to an inter-
mediate peptide, named "big" ET, of 38 to 39 amino acids. This
peptide is cleaved by a putative endopeptidase leading to the
formation of human ET [1].
The current investigation was designed to compare the effect
of pharmacological doses of ET on arterial pressure, renal
hemodynamics, sodium excretion and endogenous vasoactive
systems in conscious control and cirrhotic rats with ascites.
Bolus ET administration to control animals resulted in an
b
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in cirrhotic rats with ascites only increased significantly follow-
ing the high-dose ET administration, inhibition of tubular so-
dium reabsorption in these animals was significant with both
low- and high-dose ET.
In addition to the systemic hemodynamic and renal effects of
El, this peptide also displayed important actions on endocrine
function. Administration of ET to cirrhotic and control rats
resulted in a significant suppression of PRA. The in vivo effect
of ET on the renin-angiotensin system is not clear since
unchanged [6, 11], increased [2, 51, or decreased [121 PRA
levels have been found following ET administration to experi-
mental animals. Methodological differences may account for
those conflicting results because in these studies ET was
administered as a bolus or as a constant infusion, the doses
ranged from 4 to 2000 pmollkg, and the tested animals were
conscious or anesthetized. The decrease in PRA following ET
administration observed in the present investigation is consis-
tent with in vitro studies in isolated glomeruli [9] and dispersed
juxtaglomerular cells [81 reporting an inhibitory effect of ET on
renin release. This direct inhibitory action of ET on renin
release is supposed to be mediated by an increase in calcium
influx through dihydropyridine-insensitive calcium channels
[101. Despite the suppression in PRA, El administration was
associated with a significant increase in plasma aldosterone
concentration in both control and cirrhotic rats. Similar findings
have been observed by Goetz et alES] and by Miller, Redfield
and Burnett [2] in conscious and anesthetized normal dogs and
by Cavero et al [12] in anesthetized dogs with experimental
congestive heart failure. Since in vitro studies [13, 14, 401 have
demonstrated the presence of El receptors in cultured adrenal
zona glomerulosa cells and evidence for stimulation of aldoste-
rone secretion by ET, the mechanism by which this peptide
increased plasma aldosterone concentration is probably a direct
stimulatory effect on aldosterone synthesis.
The results of the present study, showing an increase in
plasma ANP levels following El administration to control and
cirrhotic rats, are in accordance with previous investigations
demonstrating that ET is a potent in vivo [16, 17] and in vitro
[18, 19] secretagogue for ANP. The stimulus for ANP secretion
is thought to be due to both the elevation of atrial pressure and
also to a direct effect of ET on atrial myocytes [20].
The mechanisms by which ET inhibits tubular sodium reab-
sorption in cirrhotic rats with ascites is difficult to ascertain.
The natriuretic effect of ET in these animals occurred despite a
significant increase in the plasma aldosterone concentration
which promotes sodium reabsorption in the distal nephron. It is
unlikely that the increase in arterial pressure induced by ET
accounted for the rise in urinary sodium excretion in cirrhotic
rats with ascites, since this effect was not observed by Lopez et
al [41] after producing a similar increase in arterial pressure
with norepinephrine in this experimental model. Angiotensin II
stimulates sodium reabsorption in the proximal tubule [42].
Since ET administration almost normalized PRA in cirrhotic
rats, a decrease in the intrarenal generation of angiotensin II
could play a contributory role in the natriuretic effect of El.
The marked elevation of the plasma concentration of ANP in
cirrhotic rats with ascites following El administration, which
reached values ten-fold higher than those in control animals,
could be another important factor. Although rats with Cd4-
induced cirrhosis are known to present a renal resistance to the
natriuretic action of ANP [41, 43], this resistance disappears
after increasing arterial pressure to normal values with norepi-
nephrine or angiotensin II [41]. Therefore, the hypertensive
effect of ET could increase the renal sensitivity to the natri-
uretic effect of ANP in cirrhotic rats. Finally, Zeidel et al [44]
have recently shown that ET diminishes Na-K-ATPase
activity in intact renal tubular epithelial cells by stimulating
prostaglandins synthesis. Thus, it is also possible that ET
increases sodium excretion in cirrhotic rats through inhibiting
the renal activity of the sodium pump. Further studies are
clearly needed to assess the contribution of these mechanisms
on the natriuretic effect of ET in cirrhosis with ascites.
In conclusion, and contrary to what occurs in control rats,
ET administration to conscious unrestrained rats with cirrhosis
and ascites markedly increases sodium excretion despite having
similar effects on MAP, HR, RPF, renal vascular resistance and
GFR. This natriuretic effect in cirrhotic rats occurred despite a
significant increase in plasma aldosterone concentration and in
the setting of a marked suppression of PRA and elevation of
plasma levels of ANP.
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